A Phase 2 interventional study of KH001 and Placebo in Dentin Hypersensitivity, sponsored by HysensBio Co., Ltd. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by HysensBio Co., Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Dentin Sensitivity with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Dentin Sensitivity · United States.
Among the 57 studies in Dentin Sensitivity with a site in United States, this one is the 27th largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 in phase 2, and was the 46th registered.
290 studies on the registry are indexed under Dentin Sensitivity; 48 are open to participants now.
Browse Dentin Sensitivity studies →5 of the 57 studies in Dentin Sensitivity with a site in United States are open now. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 18+
HALEON · Sites in United States
Ages 18+ · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 18–65
American Academy of Facial Esthetics · Sites in United States
Ages 20–70
University of Oklahoma · Sites in United States
Ages 18–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Dentin Sensitivity studies recruiting now, 6 (32%) set no upper age limit and 12 (63%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2024.
This study's enrollment of 120 is above the median of 60 across 281 interventional studies indexed under Dentin Sensitivity.
Median enrollment 120 across the 54 interventional studies, 1,036 across the 3 observational. Of the 50 that completed or were terminated, 40 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 57 have an industry lead sponsor. The 10 most frequent:
HysensBio Co., Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.
HysensBio Co., Ltd has 3 studies filed under Dentin Sensitivity — fewer than ten, so there is no comparison to draw.
4 of the studies in Dentin Sensitivity with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300540HALEONReal-World Study of a Calcium Sodium Phosphosilicate Anti-Sensitivity Toothpaste for Dentin Hypersensitivity Relief | 2026-11 |
| NCT07337109HALEONA Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers | 2027-02 |
| NCT07590960University of PittsburghModified Coronally Advanced Tunnel for Mandibular Lingual Root Coverage | 2027-07 |
| NCT07195357Indiana UniversityMulti-site Study to Look at Tooth Wear and Tooth Sensitivity and the Risk Factors Associated. | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 57 studies in Dentin Sensitivity with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of KH001 in subjects with dentin hypersensitivity.
The study will consist of a screening period, a treatment period, and a follow-up period. The total duration of the study for each subject will be approximately 8 to 12 weeks. All subjects will be randomly assigned in a 1:1:1 ratio, with Group A, Group B and Group C.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
KH001 and placebo
Drug: KH001 · Drug: Placebo
KH001 and placebo
Drug: KH001 · Drug: Placebo
Placebo
Drug: Placebo
Application of KH001 over a 1 or 2-week period
Applications of water for injection
Change from baseline in Schiff sensitivity score
Schiff sensitivity score 0-3 by an evaporative air
Time frame: Baseline and Week 5
Change from baseline in a Schiff sensitivity score
Schiff sensitivity score 0-3 by an evaporative air
Time frame: Baseline, Up to 8 Weeks
Change from baseline in a Tactile threshold
Tactile threshold by yeaple probe
Time frame: Baseline, Up to 8 Weeks
Change from baseline in Visual Analogue Scale
Visual Analogue Scale by an evaporative air
Time frame: Baseline, Up to 8 Weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Dec 2025, 14 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: KH001